Alex Broughton
Speaker: Alex Broughton, Queen Mary University London
Talk Title: Navigating my career Journey across Industry and Academia
Biography: Alex completed a BSc in Medical Pharmacology at Cardiff University with a Year in Industry at Simbec-Orion, a Phase 1 Clinical Research Unit. Following this, she undertook the Biopharmaceutical Development Graduate Scheme at AstraZeneca. Here she gained experience both in and out of the lab through rotations in Bioassay, Biosafety and Impurities, Cell Line Development and CMC Project Management. Since September last year, Alex has been studying for her PhD in Bioengineering with a focus on In vitro models for cardiac safety at Queen Mary University London in collaboration with AstraZeneca.
Max Harman
Speaker: Max Harman, Bicycle Therapeutics
Talk title: Off the Beaten Track: How and Why I Arrived in Industry
Biography: Max trained as a Biochemist through his undergraduate degree at the University of Bath. Max undertook a year in industry as part of this degree, working at Bicycle Therapeutics where he was then employed full time. Since, Max has spent 6 years at Bicycle developing skills as a Pharmacologist in their preclinical drug discovery group. Max has had the opportunity to grow as a biology lead in several projects, spanning from antiviral to oncology peptide therapeutics. Personally, Max enjoys working between the interface of Biology and Chemistry, contributing to several patents as an inventor and publishing several manuscripts in his time in industry so far.
Gavin Bennett
Speaker: Gavin Bennett, Bicycle Therapeutics
Talk title: TBC
Biography: Gavin Bennett undertook a BSc in Biochemistry & Physiology at the University of Sheffield, followed by a PhD in Pharmacology at King’s College London. He has been a member of the BPS since the first year of his PhD and this year became a Fellow of the Society. He has worked in Industry and Academia, on small molecules, large molecules, and molecules in between, for the treatment of diseases including inflammation, pain, neurological disorders, ophthalmology and oncology. For the last 12 years, Gavin has led the exploration of bicyclic peptides as pharmacological agents at Bicycle Therapeutics. Gavin is now the BDC Portfolio Lead, having previously led the BT5528 programme to early clinical efficacy and safety against a target previously considered intractable to toxin conjugates, demonstrating the importance of PK/PD modelling in drug development.
